by Wei Liu, Ph.D. | Jan 31, 2019 | Blog
Wei Liu, Ph.D. FollowFollowFollow Liquid biopsy gains traction as a powerful minimally invasive sampling method. Circulating cell-free DNA (cfDNA) is often analyzed from liquid biopsy samples for molecular diagnostics. cfDNA is small DNA fragments found free-floating...
by Wei Liu, Ph.D. | Nov 15, 2018 | Blog
Wei Liu, Ph.D. FollowFollowFollow Is it necessary to confirm variants from NGS?Next-generation sequencing (NGS) is a powerful tool that has seen a fast increase in clinical labs although only a few NGS tests have been approved by the FDA. However, there have been a...
by Wei Liu, Ph.D. | Oct 9, 2018 | Blog
Wei Liu, Ph.D. FollowFollowFollow Common EGFR Mutations in Non-Small Cell Lung CancerEighty five percent of the lung cancer patients are non-small cell lung cancer (NSCLC) patients. Among this population, patients with exon 19 deletion and L858R mutations respond well...
by Wei Liu, Ph.D. | Sep 11, 2018 | Blog
Month: September 2018 FollowFollowFollow Genome-wide next-generation of sequencing (NGS), such as whole genome sequencing (WGS) and whole exome sequencing (WES) has been used for germline and somatic mutation studies. However, due to the high cost and turnaround time,...
by Wei Liu, Ph.D. | Aug 22, 2018 | Blog
Month: August 2018 FollowFollowFollow Colorectal cancer (CRC), including colon and rectum cancer, is the third most common cancer in the world and the third in the US as well. American Cancer Society (ACS) estimates that there are 97,220 and 43,030 new cases in 2018...
by Wei Liu, Ph.D. | Aug 7, 2018 | Blog
Month: August 2018 FollowFollowFollow When mutated, oncogenes can convert normal cells to cancer cells. BRAF is one of the oncogenes that controls transduction of chemical signal from outside the cells to nucleus. As a member of the RAS/MAPK pathway, the BRAF gene...
Recent Comments